Aravive Announces Participation at the 2019 Piper Jaffray Healthcare Conference
December 02 2019 - 8:00AM
Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical
company developing treatments designed to halt the progression of
life-threatening diseases, including cancer and fibrosis, today
announced that company management will participate at the following
upcoming investor conference:
Event: 2019 Piper Jaffray Healthcare Conference Presentation
Date & Time: Wednesday, December 4, 2019, 9:30 AM ETLocation:
New York, NY
A live webcast of the presentation will be available at
http://ir.aravive.com.
About AraviveAravive, Inc. (Nasdaq: ARAV) is a
clinical-stage biopharmaceutical company developing treatments
designed to halt the progression of life-threatening diseases,
including cancer and fibrosis. Aravive’s lead product candidate,
AVB-500, is an ultra-high affinity decoy protein that targets the
GAS6-AXL signaling pathway. By capturing serum GAS6, AVB-500
starves the AXL pathway of its signal, potentially halting the
biological programming that promotes disease progression. AXL
receptor signaling plays an important role in multiple types of
malignancies by promoting metastasis, cancer cell survival,
resistance to treatments, and immune suppression. The GAS6-AXL
signaling pathway also plays a significant role in fibrogenesis.
Aravive has initiated the Phase 1b portion of a Phase 1b/2 clinical
trial of AVB-500 combined with standard of care therapies in
patients with platinum-resistant ovarian cancer, and intends to
expand development into additional oncology and fibrotic
indications. Aravive is based in Houston, Texas and received a
Product Development Award from the Cancer Prevention & Research
Institute of Texas (CPRIT) in 2016. Aravive was one of
FierceBiotech's Fierce 15 in 2017. For more information, please
visit www.aravive.com.
Contacts:Investors: Christina TartagliaStern
Investor Relationschristina@sternir.com
Media: Heidi Chokeir, Ph.D.Canale
Communicationsheidi@canalecomm.com
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Apr 2024 to May 2024
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From May 2023 to May 2024